{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
AnaptysBio, Inc.
AnaptysBio Hits Day High with Strong 7.66% Intraday Surge
AnaptysBio, Inc. has experienced notable stock activity, achieving a significant intraday high on October 15, 2025. While the company has shown impressive short-term gains and resilience year-to-date, it faces challenges with operating losses and a weak long-term financial outlook amid a complex industry landscape.
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
AnaptysBio, Inc. has recently revised its evaluation amid significant market volatility, with a stock price of $30.25. The company has shown notable returns over various periods, outperforming the S&P 500 in the short term, while experiencing a decline over the past year, reflecting its fluctuating market position.
Is AnaptysBio, Inc. technically bullish or bearish?
As of October 3, 2025, AnaptysBio, Inc. shows a bullish technical trend, supported by strong MACD and moving averages, despite some mixed signals from Bollinger Bands and KST indicators.
Is AnaptysBio, Inc. technically bullish or bearish?
As of October 3, 2025, AnaptysBio, Inc. shows a bullish technical trend supported by positive MACD and Bollinger Bands, though slightly tempered by a mildly bearish KST signal.
Is AnaptysBio, Inc. technically bullish or bearish?
As of October 3, 2025, AnaptysBio, Inc. has a bullish technical trend, supported by positive MACD and Bollinger Bands indicators, despite some mildly bearish signals from the KST, and it has outperformed the S&P 500 in the short term while underperforming over longer periods.
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility
AnaptysBio, Inc. has recently seen a stock price increase, reflecting notable volatility over the past year. The company has outperformed the S&P 500 year-to-date, showcasing impressive returns. Technical indicators present mixed signals, suggesting both bullish and bearish trends in the short and long term.
Is AnaptysBio, Inc. technically bullish or bearish?
As of September 26, 2025, AnaptysBio, Inc. shows a mildly bullish trend with daily moving averages indicating bullishness, despite mixed signals from the weekly MACD and KST, while outperforming the S&P 500 in the short term but underperforming over the longer term.
Is AnaptysBio, Inc. technically bullish or bearish?
As of September 26, 2025, AnaptysBio, Inc. shows a mixed technical stance with a slight bullish tilt, having outperformed the S&P 500 in the past week and month, but lagging in the 1-year and 3-year periods.
Is AnaptysBio, Inc. technically bullish or bearish?
As of September 10, 2025, AnaptysBio, Inc. shows a mildly bullish trend based on daily moving averages and a year-to-date return of 59.21%, despite mixed signals from weekly indicators and underperformance over longer periods compared to the S&P 500.
Is AnaptysBio, Inc. overvalued or undervalued?
As of March 7, 2022, AnaptysBio, Inc. is considered risky and overvalued with a Price to Book Value of 20.47 and an EV to Sales ratio of 6.16, indicating significant operational challenges compared to peers like Alector, Inc. and Entrada Therapeutics, Inc.
Is AnaptysBio, Inc. overvalued or undervalued?
As of March 7, 2022, AnaptysBio, Inc. is considered overvalued and risky due to negative earnings, poor financial ratios, and significant underperformance compared to the S&P 500.
Is AnaptysBio, Inc. technically bullish or bearish?
As of June 18, 2025, AnaptysBio, Inc. shows a mildly bearish trend due to daily moving averages, mixed MACD signals, and conflicting Bollinger Bands, suggesting a cautious investment approach.
Who are in the management team of AnaptysBio, Inc.?
As of March 2022, AnaptysBio, Inc.'s management team includes Dr. James Topper (Independent Chairman), Mr. Hamza Suria (President and CEO), and several independent directors, including Mr. Hollings Renton, Dr. Magda Marquet, Dr. Dennis Fenton, Ms. Laura Hamill, and Mr. John Schmid.
What does AnaptysBio, Inc. do?
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing antibody products for inflammation and immuno-oncology. It has a market cap of approximately $699.84 million, with recent net sales of $28 million and a net loss of $39 million.
How big is AnaptysBio, Inc.?
As of Jun 18, AnaptysBio, Inc. has a market capitalization of 699.84 million and reported net sales of 111.87 million with a net profit of -140.62 million over the latest four quarters. Shareholder's funds are 70.87 million, and total assets amount to 483.83 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
